Parmax Pharma (Small Cap) Share Target 2026, 2027 To 2035
|
Parmax Pharma Limited |
|||
|
Price: ₹45.73 (-10.44%) | ||
| 52 Week Low: ₹22.60 52 Week High: ₹53.38 |
|||
| Market Capital: 11.78 Crore (Small-cap) | |||
| -> | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Parmax Pharma Share Price Target For 2026
- 1.1.1: Parmax Pharma Share Price Target Table For 2026
- 1.1.2: Short-Term Technical Outlook
- 1.2: Parmax Pharma Share Price Target For 2027
- 1.2.1: Parmax Pharma Share Price Target Table For 2027
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Parmax Pharma Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
- 3: Parmax Pharma Financial Performance
- 3.0.1: Is Parmax Pharma A Good Buy For Long Term?
Parmax Pharma, a Small Cap company has delivered 19.4% returns in 3-year with 42.7% profit margin.
To predict the Parmax Pharma's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Parmax Pharma Share Price Target For 2026
The line chart displays the monthly closing prices of Parmax Pharma with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Parmax Pharma shares in 2026, see the table below.
Parmax Pharma Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 52.48 (+14.76%) | Volatility: ATR T1 |
| 2026 Target 2 | 52.23 (+14.21%) | 123.60% Weekly Fib Ext |
| 2026 Target 1 | 47.41 (+3.67%) | Volatility: BB Upper |
| Current Price | 45.73 | Parmax Pharma's share price as of 05 Jun 2026 |
| Stop Loss 1 | 42.17 (-7.79%) | Trend: EMA9 |
| Stop Loss 2 | 38.98 (-14.77%) | Volatility: ATR S1 |
| Stop Loss 3 | 37.41 (-18.2%) | 38.20% Weekly Fib Retrace |
Short-Term Technical Outlook
Current Technical Position: Parmax Pharma is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 50-day moving average at ₹32.77 serves as the nearest technical reference point.
Historical Returns: 3-month: +56.72% | 6-month: +48.13% | 1-year: -18.44%
Parmax Pharma Share Price Target For 2027
The line chart displays the monthly closing prices of Parmax Pharma with a black line. The green line shows three potential target prices for 2027, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Parmax Pharma shares in 2027, see the table below.
Parmax Pharma Share Price Target Table For 2027
| Level | Value | Analysis |
|---|---|---|
| 2027 Target 3 | 52.48 (+14.76%) | Volatility: ATR T1 |
| 2027 Target 2 | 52.23 (+14.21%) | 123.60% Weekly Fib Ext |
| 2027 Target 1 | 47.41 (+3.67%) | Volatility: BB Upper |
| Current Price | 45.73 | Parmax Pharma's share price as of 05 Jun 2026 |
| Stop Loss 1 | 42.17 (-7.79%) | Trend: EMA9 |
| Stop Loss 2 | 38.98 (-14.77%) | Volatility: ATR S1 |
| Stop Loss 3 | 37.41 (-18.2%) | 38.20% Weekly Fib Retrace |
Long-Term Technical Outlook
52-Week Range Analysis: Parmax Pharma is currently trading near its 52-week high of ₹53.38, showing strong yearly momentum.
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: -18.44% | 3-year: +19.45% | 5-year: -36.21%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Parmax Pharma Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹45.73 | ||
| 2026 | ₹43.13 | -5.6855455937022% | ₹43.78 |
| 2027 | ₹55.30 | +28.217018316717% | ₹56.13 |
| 2028 | ₹64.85 | +17.269439421338% | ₹65.82 |
| 2029 | ₹81.33 | +25.412490362375% | ₹82.55 |
| 2030 | ₹97.46 | +19.832780031969% | ₹98.92 |
| 2031 | ₹117.25 | +20.305766468295% | ₹119.01 |
| 2032 | ₹139.16 | +18.686567164179% | ₹141.25 |
| 2033 | ₹159.40 | +14.544409313021% | ₹161.79 |
| 2034 | ₹181.27 | +13.720200752823% | ₹183.99 |
| 2035 | ₹204.76 | +12.958570088818% | ₹207.83 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Parmax Pharma Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 11.57 Crore | Market valuation of Parmax Pharma's shares. |
| Revenue (TTM) | 15.42 Crore | Total revenue generated by Parmax Pharma over the past twelve months. |
| Net Income (TTM) | -10.4 Lakh | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | 2.77% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | 42.72% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-67.38% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
1.72 | Company's total debt divided by total shareholder equity. |
| Total Debt | 5.48 Crore | Sum of Parmax Pharma's current & long-term financial obligations. |
Is Parmax Pharma A Good Buy For Long Term?
While Parmax Pharma's past 5-year returns have been impressive (78.78%), its recent performance raises concerns. With a significant revenue decline (-67.38%), negative profit margin (-42.72%), and substantial debt (5.48 Crore), the company faces challenges that may impact its long-term growth prospects. Given these factors, it is not advisable to consider Parmax Pharma as a strong buy at this time.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
